Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive

 Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive

Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive

Shots:

  • The Gate Foundation has granted $13M to fund development program addressing the lack of global family planning options. The development of once-monthly oral contraceptive will provide women with a discreet, non-invasive option to support their family planning
  • Additionally, the Gates Foundation awarded a grant to Lyndra to develop long-acting malaria therapy and will provide funds for P-II clinical study, expansion of its P-I pipeline and manufacturing scale-up
  • Lyndra’s once-monthly oral combination therapy delivers sustained, the steady-state release of estrogen and progestin improving medication adherence and health outcomes while reducing the burdens on individuals and their caregivers

Click here to­ read full press release/ article | Ref: Lyndra Therapeutics | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post